Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 550 of 3499 entries
View as:

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase: N/A Priority: Normal
NCT ID: NCT06400264 Org: User:
Start: 02/22/22 End: 01/17/23 Due: 01/17/24

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01940809 Org: User:
Start: 08/28/13 End: 03/04/22 Due: 03/04/23

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00390325 Org: User:
Start: 11/03/06 End: 12/22/22 Due: 12/22/23

Early Detection of Barrett's Esophagus

Phase: N/A Priority: Normal
NCT ID: NCT00081354 Org: User:
Start: 04/06/04 End: 05/21/20 Due: 05/21/21

Gene Therapy in Treating Patients With Cancer of The Liver

Phase: N/A Priority: Normal
NCT ID: NCT00003147 Org: User:
Start: 02/28/98 End: - Due: -

TKM 080301 for Primary or Secondary Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01437007 Org: User:
Start: 08/26/11 End: 06/21/12 Due: 06/21/13

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004888 Org: User:
Start: 01/31/01 End: 05/31/09 Due: 05/31/10

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00019396 Org: User:
Start: 02/28/98 End: 03/31/07 Due: 03/31/08

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01286272 Org: User:
Start: 04/08/11 End: 03/19/26 Due: 03/19/27

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01204476 Org: User:
Start: 10/31/10 End: - Due: -

Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

Phase: N/A Priority: Normal
NCT ID: NCT00006094 Org: User:
Start: 07/31/00 End: - Due: -

Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT00702689 Org: User:
Start: 12/15/08 End: 02/26/20 Due: 02/26/21

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

Phase: N/A Priority: Normal
NCT ID: NCT00005781 Org: User:
Start: 05/31/00 End: 09/30/00 Due: 09/30/01

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00024011 Org: User:
Start: 07/31/01 End: - Due: -

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00098956 Org: User:
Start: 01/31/05 End: 06/30/10 Due: 06/30/11

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01979536 Org: User:
Start: 11/13/13 End: 03/31/24 Due: 03/31/25

Genetic Analysis of Patients With Pseudoxanthoma Elasticum

Phase: N/A Priority: Normal
NCT ID: NCT00341419 Org: User:
Start: 02/16/05 End: 05/14/13 Due: 05/14/14

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03040986 Org: User:
Start: 07/21/17 End: 10/15/20 Due: 10/15/21

Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02706652 Org: User:
Start: 05/22/18 End: 12/01/26 Due: 12/01/27

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04340843 Org: User:
Start: 09/08/20 End: 06/16/25 Due: 06/16/26

Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005085 Org: User:
Start: 02/29/00 End: - Due: -

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Phase: N/A Priority: Normal
NCT ID: NCT02211768 Org: User:
Start: 12/08/14 End: 12/30/19 Due: 12/30/20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00089609 Org: User:
Start: 04/19/05 End: 01/09/18 Due: 01/09/19

A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00923520 Org: User:
Start: 03/25/09 End: 12/03/18 Due: 12/03/19

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003167 Org: User:
Start: 05/31/98 End: - Due: -